US2008255182A1PendingUtilityA1

Certain chemical entities, compositions, and methods

Assignee: SMITHKLINE BEECHAM CORPPriority: May 3, 2005Filed: Jan 7, 2008Published: Oct 16, 2008
Est. expiryMay 3, 2025(expired)· nominal 20-yr term from priority
C07D 235/16C07C 255/60C07C 311/37C07C 275/42C07C 235/48C07D 285/125C07C 275/40C07C 257/18C07D 295/155C07D 471/04C07D 271/06A61P 37/00C07D 263/10C07D 403/12C07C 307/10C07D 249/08C07D 277/56C07C 271/20C07C 255/57C07D 257/04C07D 235/18C07D 211/34C07D 277/42C07D 263/12C07C 235/50C07D 271/07C07C 275/26C07D 231/12C07C 259/18C07D 498/04C07D 263/32A61P 35/00C07D 233/70C07C 257/08C07D 239/36C07D 233/61C07C 255/59C07D 207/273C07D 235/26C07C 281/06C07C 235/52A61P 31/10C07D 271/113C07F 9/6506C07C 2601/02C07D 271/10C07D 235/06C07D 333/38C07C 311/46C07D 211/76C07D 261/08C07D 233/64C07C 2601/14C07D 403/10C07D 295/145C07D 213/30C07D 277/30C07D 231/14A61P 9/00C07D 413/06C07C 237/22C07D 285/02C07C 271/28C07F 9/6561C07C 271/24
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

Claims

exact text as granted — not AI-modified
1 - 46 . (canceled) 
     
     
         47 . A method for the treatment of a solid tumor comprising administering to a subject in need thereof an effective amount of at least one compound chosen from N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide and pharmaceutically acceptable salts thereof. 
     
     
         48 . A method for the treatment of a solid tumor comprising administering to a subject in need thereof an effective amount of at least one compound chosen from N-{1-[4-(8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl)-benzyl]-3-hydroxy-propyl}-3-chloro-4-isopropoxy-benzamide and pharmaceutically acceptable salts thereof. 
     
     
         49 . A method for the treatment of a solid tumor comprising administering to a subject in need thereof an effective amount of at least one compound chosen from N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-methyl-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide and pharmaceutically acceptable salts thereof. 
     
     
         50 . A method for the treatment of a solid tumor comprising administering to a subject in need thereof an effective amount of at least one compound chosen from N-(2-(2-amino-2-methyl-propionylamino)-1-{4-[8-methyl-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide and pharmaceutically acceptable salts thereof. 
     
     
         51 . A method for the treatment of a solid tumor comprising administering to a subject in need thereof an effective amount of at least one compound chosen from 3-chloro-N-((2S)-1-(2-(dimethylamino)acetamido)-3-(4-(8-(1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl)phenyl)propan-2-yl)-4-isopropoxybenzamide 
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable salts thereof. 
     
     
         52 . A method for the treatment of a solid tumor comprising administering to a subject in need thereof an effective amount of at least one compound chosen from (S)-3-chloro-N-(1-(2-(dimethylamino)acetamido)-3-(4-(8-methylimidazo[1,2-a]pyridin-2-yl)phenyl)propan-2-yl)-4-isopropoxybenzamide 
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable salts thereof. 
     
     
         53 . A method for the treatment of a solid tumor comprising administering to a subject in need thereof an effective amount of at least one compound chosen from (S)—N-(1-(2-amino-2-methylpropanamido)-3-(4-(8-methylimidazo[1,2-a]pyridin-2-yl)phenyl)propan-2-yl)-3-chloro-4-isopropoxybenzamide 
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable salts thereof.

Join the waitlist — get patent alerts

Track US2008255182A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.